Shin Poong Pharm.Co.,Ltd. (019170.KS)
KRW 10370.0
(-5.04%)
KRW 10370.0
(-5.04%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 218.96 Million KRW | -50.41% |
| 2022 | 441.51 Million KRW | 107.61% |
| 2021 | 212.66 Million KRW | -63.07% |
| 2020 | 575.85 Million KRW | -92.49% |
| 2019 | 7.66 Billion KRW | 283.18% |
| 2018 | 2 Billion KRW | -79.06% |
| 2017 | 9.55 Billion KRW | 18.63% |
| 2016 | 8.05 Billion KRW | 79.96% |
| 2015 | 4.47 Billion KRW | -54.51% |
| 2014 | 9.83 Billion KRW | -67.34% |
| 2013 | 30.11 Billion KRW | 159.47% |
| 2012 | 11.6 Billion KRW | -41.53% |
| 2011 | 19.84 Billion KRW | -2.23% |
| 2010 | 20.3 Billion KRW | -48.85% |
| 2009 | 39.69 Billion KRW | 7.97% |
| 2008 | 36.76 Billion KRW | 168.2% |
| 2007 | 13.7 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 189.24 Million KRW | 0.0% |
| 2024 Q2 | - KRW | 0.0% |
| 2023 Q1 | 217.14 Million KRW | -50.82% |
| 2023 Q3 | 297.07 Million KRW | 145.44% |
| 2023 FY | 218.96 Million KRW | -50.41% |
| 2023 Q2 | 121.03 Million KRW | -44.26% |
| 2023 Q4 | 218.96 Million KRW | -26.29% |
| 2022 Q2 | 767.99 Million KRW | -2.49% |
| 2022 Q4 | 441.51 Million KRW | -41.19% |
| 2022 FY | 441.51 Million KRW | 107.61% |
| 2022 Q1 | 787.63 Million KRW | 270.36% |
| 2022 Q3 | 750.71 Million KRW | -2.25% |
| 2021 Q4 | 212.66 Million KRW | -32.89% |
| 2021 Q1 | 519.98 Million KRW | -9.7% |
| 2021 Q2 | 417.59 Million KRW | -19.69% |
| 2021 FY | 212.66 Million KRW | -63.07% |
| 2021 Q3 | 316.91 Million KRW | -24.11% |
| 2020 Q3 | 28.98 Billion KRW | 193.81% |
| 2020 Q2 | 9.86 Billion KRW | 0.43% |
| 2020 Q1 | 9.82 Billion KRW | 28.16% |
| 2020 FY | 575.85 Million KRW | -92.49% |
| 2020 Q4 | 575.85 Million KRW | -98.01% |
| 2019 Q1 | 5.58 Billion KRW | 179.32% |
| 2019 FY | 7.66 Billion KRW | 283.18% |
| 2019 Q4 | 7.66 Billion KRW | -0.58% |
| 2019 Q3 | 7.7 Billion KRW | 61.92% |
| 2019 Q2 | 4.76 Billion KRW | -14.78% |
| 2018 Q2 | 5 Billion KRW | -47.64% |
| 2018 Q4 | 2 Billion KRW | -60.0% |
| 2018 Q3 | 5 Billion KRW | 0.0% |
| 2018 FY | 2 Billion KRW | -79.06% |
| 2018 Q1 | 9.55 Billion KRW | 0.0% |
| 2017 Q3 | 9.55 Billion KRW | 0.0% |
| 2017 Q1 | 9.8 Billion KRW | 21.74% |
| 2017 FY | 9.55 Billion KRW | 18.63% |
| 2017 Q4 | 9.55 Billion KRW | 0.0% |
| 2017 Q2 | 9.55 Billion KRW | -2.55% |
| 2016 FY | 8.05 Billion KRW | 79.96% |
| 2016 Q3 | 8.39 Billion KRW | 46.4% |
| 2016 Q4 | 8.05 Billion KRW | -4.08% |
| 2016 Q2 | 5.73 Billion KRW | -5.58% |
| 2016 Q1 | 6.07 Billion KRW | 35.71% |
| 2015 Q3 | 5.59 Billion KRW | -42.41% |
| 2015 Q1 | 8.58 Billion KRW | -12.69% |
| 2015 FY | 4.47 Billion KRW | -54.51% |
| 2015 Q4 | 4.47 Billion KRW | -20.06% |
| 2015 Q2 | 9.71 Billion KRW | 13.17% |
| 2014 FY | 9.83 Billion KRW | -67.34% |
| 2014 Q3 | 31.62 Billion KRW | -10.08% |
| 2014 Q4 | 9.83 Billion KRW | -68.9% |
| 2014 Q2 | 35.16 Billion KRW | 5.97% |
| 2014 Q1 | 33.18 Billion KRW | 10.2% |
| 2013 Q1 | 10.14 Billion KRW | -12.55% |
| 2013 Q4 | 30.11 Billion KRW | 222.97% |
| 2013 FY | 30.11 Billion KRW | 159.47% |
| 2013 Q2 | 8.65 Billion KRW | -14.72% |
| 2013 Q3 | 9.32 Billion KRW | 7.72% |
| 2012 Q1 | 17.69 Billion KRW | 0.0% |
| 2012 Q4 | 11.6 Billion KRW | 0.0% |
| 2012 FY | 11.6 Billion KRW | -41.53% |
| 2011 Q2 | 16.81 Billion KRW | -8.75% |
| 2011 FY | 19.84 Billion KRW | -2.23% |
| 2011 Q3 | 22.04 Billion KRW | 31.07% |
| 2011 Q1 | 18.42 Billion KRW | 0.0% |
| 2010 Q2 | 39 Billion KRW | 1.96% |
| 2010 FY | 20.3 Billion KRW | -48.85% |
| 2010 Q3 | 36.49 Billion KRW | -6.44% |
| 2010 Q1 | 38.25 Billion KRW | 0.0% |
| 2009 Q2 | 35.1 Billion KRW | -15.56% |
| 2009 FY | 39.69 Billion KRW | 7.97% |
| 2009 Q3 | 37.99 Billion KRW | 8.22% |
| 2009 Q1 | 41.57 Billion KRW | 0.0% |
| 2008 FY | 36.76 Billion KRW | 168.2% |
| 2008 Q2 | 22.17 Billion KRW | 33.96% |
| 2008 Q1 | 16.55 Billion KRW | 0.0% |
| 2008 Q3 | 30.98 Billion KRW | 39.73% |
| 2007 Q2 | 6.11 Billion KRW | 447.68% |
| 2007 Q3 | 9.21 Billion KRW | 50.62% |
| 2007 FY | 13.7 Billion KRW | 0.0% |
| 2007 Q1 | 1.11 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 98.395% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 99.892% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | 99.267% |
| HANDOK Inc. | 123.78 Billion KRW | 99.823% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | 53.975% |
| Yuhan Corporation | 60.23 Billion KRW | 99.636% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 99.865% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -115.052% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 99.733% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | 62.907% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 96.381% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | 98.818% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | 98.26% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | 86.305% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 98.395% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -82.958% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 99.819% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 99.316% |
| JW Holdings Corporation | 20.65 Billion KRW | 98.94% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | 98.523% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | 99.27% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 99.27% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | 62.29% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 99.558% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | 95.082% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 98.395% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | 98.849% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 99.766% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 99.27% |
| Yuhan Corporation | 60.23 Billion KRW | 99.636% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | 97.915% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 99.458% |
| Suheung Co., Ltd. | 74 Billion KRW | 99.704% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 99.27% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | 94.745% |
| Korea United Pharm Inc. | 10.96 Billion KRW | 98.003% |
| CKD Bio Corp. | 69.43 Billion KRW | 99.685% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 99.367% |
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | 98.642% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | 28.69% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | 0.0% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 99.696% |
| Boryung Corporation | 151.7 Billion KRW | 99.856% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 99.721% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 96.381% |
| JW Lifescience Corporation | 168 Million KRW | -30.334% |